Comparative effectiveness of two lipid emulsions in preventing retinopathy of prematurity in preterm infants requiring parenteral nutrition

IF 1 Q4 PHARMACOLOGY & PHARMACY

FARMACIA HOSPITALARIA Pub Date : 2024-07-01 DOI:10.1016/j.farma.2023.10.005

Mª José Cabañas Poy , José Bruno Montoro Ronsano , Félix Castillo Salinas , Nieves Martín-Begué , Susana Clemente Bautista , Mª Queralt Gorgas Torner

{"title":"Comparative effectiveness of two lipid emulsions in preventing retinopathy of prematurity in preterm infants requiring parenteral nutrition","authors":"Mª José Cabañas Poy , José Bruno Montoro Ronsano , Félix Castillo Salinas , Nieves Martín-Begué , Susana Clemente Bautista , Mª Queralt Gorgas Torner","doi":"10.1016/j.farma.2023.10.005","DOIUrl":null,"url":null,"abstract":"<div><h3>Objectives</h3><p>The main aim was to compare the effects of 2 parenteral lipid emulsions on retinopathy of prematurity (ROP) incidence, severity, and need for treatment. Secondary aim was to compare the effect on weight gain in the first 6 weeks of life.</p></div><div><h3>Methods</h3><p>Single-center, observational, retrospective study analyzing preterm infants with a gestational age (GA) <31 weeks and a birth weight <1251 g born between April 2015 and December 2018. The infants' medical records were reviewed to collect clinical data. Parenteral nutrition (PN) details were obtained from the hospital pharmacy database.</p></div><div><h3>Results</h3><p>In total, 180 patients were included: 90 received ClinOleic® and 90 received SMOFlipid®. No significant differences were observed for the incidence of ROP (40% in ClinOleic® group and 41% in SMOFlipid® group, <em>p</em>  =.152). Weekly weight gain was similar in the 2 groups.</p></div><div><h3>Conclusions</h3><p>This study showed no difference between the 2 groups regarding ROP, ROP requiring treatment, or weekly weight gain in the first 6 weeks of life.</p></div>","PeriodicalId":45860,"journal":{"name":"FARMACIA HOSPITALARIA","volume":null,"pages":null},"PeriodicalIF":1.0000,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1130634323009017/pdfft?md5=adaef8288dc797f7634a54fd37182a9b&pid=1-s2.0-S1130634323009017-main.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"FARMACIA HOSPITALARIA","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1130634323009017","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

Abstract

Objectives

The main aim was to compare the effects of 2 parenteral lipid emulsions on retinopathy of prematurity (ROP) incidence, severity, and need for treatment. Secondary aim was to compare the effect on weight gain in the first 6 weeks of life.

Methods

Single-center, observational, retrospective study analyzing preterm infants with a gestational age (GA) < 31 weeks and a birth weight < 1251 g born between April 2015 and December 2018. The infants' medical records were reviewed to collect clinical data. Parenteral nutrition (PN) details were obtained from the hospital pharmacy database.

Results

In total, 180 patients were included: 90 received ClinOleic® and 90 received SMOFlipid®. No significant differences were observed for the incidence of ROP (40% in ClinOleic® group and 41% in SMOFlipid® group, p = .88) or ROP requiring treatment (4% and 10%, respectively, p = .152). Weekly weight gain was similar in the 2 groups.

Conclusions

This study showed no difference between the 2 groups regarding ROP, ROP requiring treatment, or weekly weight gain in the first 6 weeks of life.

查看原文本刊更多论文

两种脂质乳剂在预防需要肠外营养的早产儿早产视网膜病变方面的效果比较。

研究目的主要目的是比较两种肠外脂质乳剂对早产儿视网膜病变（ROP）发病率、严重程度和治疗需求的影响。次要目的是比较对出生后前 6 周体重增加的影响：单中心、观察性、回顾性研究，分析早产儿的胎龄（GA）结果：共纳入 180 名患者：90名患者接受了ClinOleic®治疗，90名患者接受了SMOFlipid®治疗。在视网膜病变的发生率（ClinOleic®组为40%，SMOFlipid®组为41%，P=.88）和需要治疗的视网膜病变发生率（分别为4%和10%，P=.152）方面没有观察到明显差异。两组每周体重增加情况相似：这项研究表明，两组患儿在出生后头6周内的视网膜病变、需要治疗的视网膜病变或每周体重增加方面没有差异。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

FARMACIA HOSPITALARIA PHARMACOLOGY & PHARMACY-

CiteScore

1.90

自引率

21.40%

发文量

审稿时长

37 days

期刊介绍： Una gran revista para acceder a los mejores artículos originales y revisiones de la farmacoterapia actual. Además, es Órgano de expresión científica de la Sociedad Española de Farmacia Hospitalaria, y está indexada en Index Medicus/Medline, EMBASE/Excerpta Médica, Alert, Internacional Pharmaceutical Abstracts y SCOPUS.